CG Oncology (NASDAQ:CGON - Get Free Report) is projected to post its quarterly earnings results before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.37) per share and revenue of $0.11 million for the quarter.
CG Oncology Trading Down 2.4 %
CG Oncology stock traded down $0.67 on Friday, hitting $27.09. The company's stock had a trading volume of 469,892 shares, compared to its average volume of 632,903. CG Oncology has a one year low of $23.91 and a one year high of $46.99. The company has a fifty day moving average price of $28.14 and a 200-day moving average price of $32.27.
Analysts Set New Price Targets
Several research firms recently issued reports on CGON. HC Wainwright reissued a "buy" rating and issued a $75.00 price target on shares of CG Oncology in a research report on Friday, January 10th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $66.00 price target on shares of CG Oncology in a research note on Friday, December 6th. TD Cowen assumed coverage on CG Oncology in a research report on Tuesday, January 7th. They issued a "buy" rating on the stock. Finally, Morgan Stanley restated an "overweight" rating and issued a $55.00 target price on shares of CG Oncology in a research note on Friday, March 7th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, CG Oncology presently has a consensus rating of "Buy" and an average price target of $63.88.
Get Our Latest Stock Report on CG Oncology
Insider Buying and Selling
In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the stock in a transaction on Monday, January 13th. The stock was sold at an average price of $29.66, for a total value of $29,660.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
About CG Oncology
(
Get Free Report)
CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.
Featured Stories
Before you consider CG Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.
While CG Oncology currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
